Allorion Therapeutics announced that it has received $50 million in a round of funding led by new investor INCE Management Consulting (Shanghai) Co., Ltd., and returning investor Qiming Weichuang Venture Capital Management (Shanghai) Company Limited on March 9, 2023. The transaction included participation from 3SBio, and new investor Long River Investments and returning investors TF Capital, Octagon Capital Advisors LP, Elikon Venture. The company has received $100 million funding till date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.76 HKD | +1.50% |
|
+4.81% | -10.11% |
Jun. 25 | 3Sbio Inc. Declares Final Dividend for the Year Ended 31 December 2023, Payable on 5 August 2024 | CI |
Jun. 25 | 3Sbio Inc. Announces Board Changes | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.11% | 2.04B | |
+6.96% | 101B | |
+8.29% | 42.63B | |
-11.09% | 33.5B | |
+82.32% | 29.77B | |
-11.82% | 16.14B | |
+1.39% | 14.31B | |
-12.13% | 11.55B | |
+176.65% | 10.53B | |
+6.74% | 9.2B |
- Stock Market
- Equities
- 1530 Stock
- News 3SBio Inc.
- Allorion Therapeutics announced that it has received $50 million in funding from a group of investors